Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models

被引:43
作者
Bertilaccio, Maria Teresa Sabrina [2 ]
Simonetti, Giorgia [2 ,3 ]
Dagklis, Antonis [2 ]
Rocchi, Martina [4 ]
Rodriguez, Tania Veliz [2 ]
Apollonio, Benedetta [1 ,2 ]
Mantovani, Alberto [5 ]
Ponzoni, Maurilio [4 ,6 ]
Ghia, Paolo [2 ,5 ]
Garlanda, Cecilia [1 ,5 ]
Caligaris-Cappio, Federico [1 ,2 ,5 ]
Muzio, Marta [2 ]
机构
[1] Univ Vita Salute San Raffaele, I-20132 Milan, Italy
[2] Ist Sci San Raffaele, Div Mol Oncol, I-20132 Milan, Italy
[3] Univ Milano Bicocca, Milan, Italy
[4] Ist Sci San Raffaele, Pathol Unit, I-20132 Milan, Italy
[5] IRCCS, Ist Clin Humaritas, Lab Immunol & Inflammat, Milan, Italy
[6] Ist Sci San Raffaele, Dept Oncol, Clin Unit Lymphoid Malignancies, I-20132 Milan, Italy
关键词
TOLL-LIKE RECEPTORS; T-CELL POLARIZATION; ACTIVATE B-CELLS; PROLYMPHOCYTIC LEUKEMIA; INHIBITORY MEMBER; SUBSEQUENT RISK; INNATE IMMUNITY; FAMILY-MEMBER; CANCER-CELLS; EXPRESSION;
D O I
10.1182/blood-2011-01-329870
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Inflammation is involved in the initiation and progression of several chronic lymphoid malignancies of B-cell type. Toll-like receptors (TLR) are transmembrane inflammatory receptors that on recognition of pathogen-associated molecular patterns trigger an innate immune response and bridge the innate and adaptive immune response by acting as costimulatory signals for B cells. Fine tuning of TLR and IL-1R-like (ILR) activity is regulated by TIR8 (SIGIRR), a transmembrane receptor of the TLR/ILR family which inhibits other family members. To test the hypothesis that TLR and/or ILR may play a role in the natural history of chronic B-cell tumors, we crossed E mu-TCL1 transgenic mice, a well established model of chronic lymphocytic leukemia (CLL), with mice lacking the inhibitory receptor TIR8 that allow an unabated TLR-mediated stimulation. We here report that in the absence of TIR8 the appearance of monoclonal B-cell expansions is accelerated and mouse life span is shortened. The morphology and phenotype of the mouse leukemic expansions reproduce the progression of human CLL into an aggressive and frequently terminal phase characterized by the appearance of prolymphocytes. This study reveals an important pathogenetic implication of TLR in CLL development and progression. (Blood. 2011;118(3):660-669)
引用
收藏
页码:660 / 669
页数:10
相关论文
共 50 条
  • [31] MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia
    Visone, Rosa
    Veronese, Angelo
    Balatti, Veronica
    Croce, Carlo M.
    ONCOTARGET, 2012, 3 (02) : 195 - 202
  • [32] BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemia
    Zenz, Thorsten
    Benner, Axel
    Duehrsen, Ulrich
    Duerig, Jan
    Doehner, Hartmut
    Siffert, Winfried
    Stilgenbauer, Stephan
    Nueckel, Holger
    LEUKEMIA & LYMPHOMA, 2009, 50 (11) : 1837 - 1842
  • [33] Impact Of TP53 Gene Promoter Methylation On Chronic Lymphocytic Leukemia Pathogenesis And Progression
    Saeed, Waleed Haji
    Eissa, Adil Abozaid
    Al-Doski, Adnan Anwar
    JOURNAL OF BLOOD MEDICINE, 2019, 10 : 399 - 404
  • [34] The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia
    Stankovic, Tatjana
    Skowronska, Anna
    LEUKEMIA & LYMPHOMA, 2014, 55 (06) : 1227 - 1239
  • [35] Suppression of chronic lymphocytic leukemia progression by CXCR4 inhibitor WZ811
    Li, Shi Hui
    Dong, Wen Chuan
    Fan, Li
    Wang, Guang Sheng
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2016, 8 (09): : 3812 - 3821
  • [36] FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia
    Nueckel, Holger
    Collins, Crista H.
    Frey, Ulrich H.
    Sellmann, Ludger
    Duerig, Jan
    Siffert, Winfried
    Duehrsen, Ulrich
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 83 (06) : 541 - 549
  • [37] Glyoxalase 1 inhibitor BBGC suppresses the progression of chronic lymphocytic leukemia and promotes the efficacy of Palbociclib
    Tang, Jiameng
    Zhong, Jialing
    Yang, Zheng
    Su, Qisheng
    Mo, Wuning
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2023, 650 : 96 - 102
  • [38] Chronic lymphocytic leukemia and proteomics: protein profiles and links with disease progression still need validation
    Zent, Clive S.
    LEUKEMIA & LYMPHOMA, 2016, 57 (05) : 985 - 986
  • [39] Multiparametric analysis of CD8+ T cell compartment phenotype in chronic lymphocytic leukemia reveals a signature associated with progression toward therapy
    Gonnord, Pauline
    Costa, Manon
    Abreu, Arnaud
    Peres, Michael
    Ysebaert, Loic
    Gadat, Sebastien
    Valitutti, Salvatore
    ONCOIMMUNOLOGY, 2019, 8 (04):
  • [40] A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression br
    Abrisqueta, Pau
    Medina, Daniel
    Villacampa, Guillermo
    Lu, Junyan
    Alcoceba, Miguel
    Carabia, Julia
    Boix, Joan
    Tazon-Vega, Barbara
    Iacoboni, Gloria
    Bobillo, Sabela
    Marin-Niebla, Ana
    Gonzalez, Marcos
    Zenz, Thorsten
    Crespo, Marta
    Bosch, Francesc
    BLOOD ADVANCES, 2022, 6 (21) : 5763 - 5773